Neumora Therapeutics Inc....

1.21
0.08 (7.08%)
At close: Mar 24, 2025, 2:51 PM

Neumora Therapeutics Common Stock Income Statement

Year FY24 FY23 FY22 FY21 FY20
Revenue n/a n/a n/a n/a n/a
Cost of Revenue n/a 668K 2.7M 1.55M n/a
Gross Profit n/a -668K -2.7M -1.55M n/a
Operating Income -263.46M -188.19M -135.87M -237.32M -95.52M
Interest Income 19.93M 16.61M 4.56M n/a n/a
Pretax Income -243.61M -235.66M -130.9M -237.31M -99.27M
Net Income -243.79M -235.93M -130.9M -237.31M -99.27M
Selling & General & Admin 62.54M 44.81M 31.12M 24.55M 8.39M
Research & Development 200.93M 142.72M 104.75M 212.78M 87.13M
Other Expenses n/a n/a 405K 11K -3.75M
Operating Expenses 263.46M 187.53M 135.87M 237.32M 95.52M
Interest Expense n/a n/a n/a n/a n/a
Selling & Marketing Expenses n/a -668K n/a n/a n/a
Cost & Expenses n/a 188.19M 135.87M 237.32M 95.52M
Income Tax 178K 268K -4.56M 301.44K -101.3K
Shares Outstanding (Basic) 159.38M 158.83M 151.95M 151.95M 151.95M
Shares Outstanding (Diluted) 159.38M 158.83M 151.95M 151.95M 151.95M
EPS (Basic) -1.53 -1.49 -0.86 -1.56 -0.65
EPS (Diluted) -1.53 -1.49 -0.86 -1.56 -0.65
EBITDA -263.46M -187.53M -135.28M -236.78M -95.41M
Depreciation & Amortization n/a 668K 2.7M 1.55M 105K